Q2 2024 AngioDynamics Inc Earnings Call

Presentation

Operator

Good morning and welcome to the AngioDynamics fiscal year 2024 second quarter earnings call. (Operator Instructions) As a reminder, this conference call is being recorded. The news release detailing AngioDynamics' fiscal 2024 second quarter results crossed the wire earlier this morning and is available on the company's website.
This conference call is also being broadcast live over the Internet at the investors section of the company's website at www.angiodynamics.com and the webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I would like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings, and gross margins for fiscal year 2024, as well as trends that may continue.
Management encourages you to review the company's past and future filings with the SEC, including without limitation the company's Forms 10-Q and 10-K which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements.
The company will also discuss certain non-GAAP and pro forma financial measures during this call. Management uses these measures to establish operational goals and review operational performance and believes that these measures may assist investors in analyzing the underlying trends in the company's business over time. Investors should consider these non-GAAP and pro forma measures in addition to not as a substitute for or superior to financial reporting measures prepared in accordance with GAAP.
A slide package offering insight into the company's financial results is also available on the investors section of the company's website under Events and Presentations. This presentation should be read in conjunction with the press release discussing the company's operating results and financial performance during this morning's conference call. I'd now like to turn the call over to Jim Clemmer, AngioDynamics' President and Chief Executive Officer. Mr. Clemens?

Thank you, Rob, and good morning, everyone, and thanks for joining us today for our fiscal 2024 second quarter earnings call. Joining me on today's call is Steve Trowbridge, AngioDynamics' Executive Vice President and Chief Financial Officer, who will provide a more detailed analysis of our second quarter financial performance as well as the manufacturing and restructuring that we announced this morning. Unless otherwise noted, all financial metrics and growth rates provided during the call today with respect to our results will be on a pro forma basis, which excludes the impact of our divested Dialysis and BioSentry businesses.
Before digging into our quarterly results, we are announcing significant steps in our long-term strategic transformation. During the second quarter, we continued to actively pursue portfolio optimization opportunities, and we made progress on that front. In addition, this morning, we announced a planned restructuring of our manufacturing footprint by moving to a fully outsourced model.
With these moves, we will remain focused on generating continued growth across both our med tech and med device businesses while simultaneously driving margin expansion. Importantly, when the dust settles from our initiatives at the end of our two year plan, we expect to achieve full year profitability in FY 2027. Both Steve and I will go into additional details later in the call. But now let me get back to Q2.
Our second quarter of fiscal '24 saw year-over-year growth, but we also faced headwinds, particularly in our thrombectomy business. We ended the second quarter with revenue of $79.1 million representing growth of approximately 3% over year, led by growth of approximately 4% from our med tech segment. While growth of the med tech segment was bit behind our expectations, particularly in mechanical thrombectomy, our adjusted EPS was a loss of $0.05 as we remained focused on our spending in managing operating expenses while still investing in long-term growth.
Our mechanical thrombectomy business which includes AngioVac and AlphaVac, declined 4.7% year over year. We are disappointed by these results as clearly the growth trajectory of this business is taking longer to inflect than we had expected. We attribute some of the softness to slightly weaker than anticipated procedural volumes late in our quarter. But we also believe the steps we are taking to drive this business are gaining positive traction.
For example, following on the heels of receiving the breakthrough designation for the use of AngioVac to remove Right Heart Vegetation, we continue working diligently with the FDA toward receiving final approval to begin our IDE study. While AlphaVac revenues were softer than we would have liked this quarter, what we've learned over the past 18 months is that physicians value this durability, simplicity, and safety of the device. And we look forward to the introduction of two new second-generation design enhancements that will make the product even more appealing later calendar 2024.
As announced in early December, we enrolled our final patient in our APEX AV study, which is designed to assess the performance of the AlphaVac F18 system in reducing thrombus burden and improving right ventricular function. We look forward to collecting data from this study at the 30-day follow-up stage, then submitting our data to the FDA in the early part of calendar year 2024 to support an expanded indication for AlphaVac F18 to treat pulmonary embolism.
We believe the softer than anticipated AlphaVac sales during the quarter partially stem from a wind down of many of our sites as we approach the completion of enrollment in the APEX PE trial, and we expect some continued softness between the completion of the trial and the FDA approval of the PE indication as the device does not have a specific PE clearance and is competing against two existing products that do.
We fully expect that once we receive our anticipated approval letter later this calendar year, we will have a highly competitive and differentiated product in what remains a large, underpenetrated, high-growth market. Because of the tremendous interest from the physician community, we were able to complete our study as quickly as we did in a time that outpaced the previous competitive studies, and we are excited about the path ahead.
Turning to our NanoKnife business, we saw sales grow approximately 2.8% during the second quarter, with sales of probes declining 3.6%. Probe sales grew in the US, but declined internationally due to timing of both bringing on new distributors during the previous year's quarter and distributor orders during this year's quarter.
Stronger international capital sales during the quarter offset the decline in probes and will drive additional pro-growth in future periods as those units come online. Year to date, NanoKnife probes were up 12.9% and total NanoKnife sales are up 16.7%. We continue to expect strong growth from this business on an annual basis, while anticipating quarter-to-quarter fluctuations in both probes and capital sales as historically has been the case.
During the second quarter, we saw solid growth of our Auryon platform, up 12.9% year over year and we're excited to tell you that in November, we reached an important milestone, having achieved $100 million in cumulative revenue since we launched this product in September of 2020.
We did experience some delays in sales related to the recent increased attention around pre-authorizations. But we believe that over the long term, the unique way that we deliver laser energy and safely treat disease vessels will continue to drive increased share and provide the foundation for continued strong growth.
Growth of approximately 2% in our med device segments was primarily driven by angiographic catheter products and our ports, which grew 8% and 5.5%, respectively. In the second quarter of FY 2024, our international business grew 12.6% year over year with double digit growth from both our med tech and our med device segment. We also hosted our third international clinical live symposium which has led to increased interest in our med tech products and we have generated a meaningful pipeline of global physicians who are excited to utilize our products in caring for their patients.
Now turning to our strategic initiatives that I mentioned earlier, we told you over the past several quarters that we were further evaluating the products in our med device portfolio, and we remain engaged in active discussions to do just that. We advanced this initiative during the second quarter, and we look forward to providing you with additional details soon when we are able to.
In addition to our continued portfolio optimization efforts, we are also increasing our focus on reducing structural costs within our manufacturing footprint and transitioning our upstate New York manufacturing operations to a fully outsourced model over the next two years.
As a reminder, roughly 80% of our med tech revenue is already leveraging this third party manufacturing model. As many of you already know, we began moving some of our med device manufacturing capacity to Costa Rica over the past couple of years as we began to see labor shortages in our upstate New York facilities.
Fully moving both med tech and med device to this model will drive an annualized savings of roughly $15 million by our FY27, driving significant gross margin improvement and equally as important, giving us a pathway to full year profitability by FY27. Steve will cover this in more detail, but we believe this is a significant advancement of our long-term strategy that simplifies our operations while allowing us to invest in the long-term growth of our med tech portfolio and the overall business while still driving profitability.
Shifting back to the near term, we're excited for what lies ahead in calendar 2024. This month, we will commence the limited market release of our Auryon radial catheter, which will provide physicians an access point at the wrist, enabling faster, less invasive procedures.
This release will be the first of six planned product releases for Auryon during calendar year 2024. In the second half of year of calendar year 2024, we will launch two new design enhancements for AlphaVac designed around physician feedback we've received, and we'll provide more details on those as we get closer to launch.
We've also got an exciting schedule of regulatory clearances on the horizon. We are projecting EU approval of Auryon and AlphaVac PE in the first half of calendar year 2024. Next, we also expect US approval of AlphaVac PE mid calendar year. And then finally, in July, the preserved 12-month follow-up will be complete, putting us on track for potential FDA approval in late calendar 2024 or early calendar 2025.
These introductions and regulatory clearances are critical parts of the strategy that we laid out for you in our July 2021 Investor & Technology Day. These open up significantly larger, higher growth addressable markets. We are excited about the strategic initiatives that we've shared with you this morning and about the future of our portfolio, and we hope the impacts of our strategic transformation of becoming more apparent each quarter.
With that, I'll turn the call over to Steve Trowbridge to review the quarter in more detail. Steve?

Thanks, Jim, and good morning, everyone. Before I begin, I'd like to direct everyone to the presentation on our Investor Relations website summarizing the key items from our quarterly results. As Jim mentioned, unless otherwise noted, all metrics and growth rates mentioned during today's call are on a pro forma basis and exclude the results of the Dialysis and BioSentry businesses that we divested in mid-June.
Similar to Jim, I'll start with the second quarter before shifting to today's strategic announcements. Our revenue for the second quarter of FY24 increased 2.7% year over year to $79.1 million, driven by growth in both our med tech and med device platform. Med tech revenue was $25.4 million, a 3.5% year over year increase, while med device revenue was $53.7 million, growing 2.3% compared to the second quarter of FY23.
Year to date, our overall revenue was up 4.2% year over year with our med tech segment up 8.3% and our med device segment up 2.3%. For the second fiscal quarter, our mid tech platforms comprised 32.1% of our total revenue compared to 31.8% of total revenue a year ago. For the six months ended November 30, 2023, our med tech segment comprised 32.6% of our total revenue base versus 31.4% as of one year ago.
Our Auryon platform contribute $11.4 million in revenue during the second quarter growing 12.9% compared to last year. Year to date, our Auryon platform is up 18.9% year over year. Mechanical thrombectomy revenue, which includes AngioVac and AlphaVac sales declined 4.7% over the second quarter of FY23. AlphaVac revenue for the second quarter was $1.9 million. AngioVac revenue was $5.4 million in the quarter, representing a decline of 10.8% over the prior year.
And we did not see the rebound in AngioVac revenues that we had anticipated as procedure volumes came in lighter than expected, particularly late in the quarter. We remain confident that mechanical thrombectomy will be a strategic contributor to our long-term growth strategy, and we are excited about the new product introductions that Jim mentioned, as well as our clinical initiatives such as the APEX pulmonary embolism study.
NanoKnife disposable revenue during the quarter decreased 3.6% year over year. Disposable growth of 4% in the US was offset by a year-over-year decline in international markets. As Jim said, the year-over-year quarterly decline in international markets was primarily driven by timing of distributor orders, although procedure volume remained very strong during the quarter.
Capital sales were robust in the quarter, growing 22.8%, and this is a strong driver of future disposable sales. Year to date, NanoKnife disposable sales are up 12.9% and total NanoKnife sales are up 16.7%. In addition, as a reminder, earlier this year, we announced that enrollment in preserve is now 100% complete. And as this data starts to be made public over the course of this year, we look forward to sharing it with you.
In the second quarter, our med device segment grew 2.3% year over year, led by strength in our angiographic catheter and port products. Moving down the income statement, our gross margin for the second quarter of FY24 was 50.9%, a decrease of 80 basis points compared to the year ago period. For the second fiscal quarter, med tech gross margin was 62.4%, a decrease of 130 basis points, and med device gross margin was 45.5%, a decrease of 60 basis points each when compared to the second quarter of last year.
Year to date, gross margin for FY24 was 50.8%, a decrease of 60 basis points versus prior year, with med tech gross margins of 63.5% and med device gross margins of 44.7%. Year-over-year gross margins for both the quarter and year to date were positively impacted by sales volume, production volume, and reduced costs for both freight expenses and direct labor retention payments, but were offset by sales mix, hardware placements and continued, albeit reduced material and labor inflation.
As we discussed, our strategic business model contemplates gross margin expansion as our higher-margin med tech segment continues to become a larger portion of our overall revenue base. As mentioned last quarter, the next phase of our transformation is to address the scale and structural limitations of our operating footprint in a capital-efficient manner.
This morning's announcement regarding restructuring our manufacturing footprint and transitioning our upstate New York manufacturing operations to a fully outsourced model will address these structural cost limitations, meaningfully improved gross margins, and lead to full year adjusted EPS profitability in FY27. We expect that our manufacturing restructuring will result in annualized savings of roughly $15 million with the full annualized impact being realized in FY27. In addition, as we previously discussed, we're continuing to have productive conversations around further optimizing our portfolio, and we will provide you with more details when appropriate.
Turning to R&D, our research and development expense during the second quarter of FY24 was $8.7 million or 10.9% of sales compared to $6.8 million or 8.8% of sales a year ago. Spending on clinical programs was 18.8% of total R&D spend during the second quarter of fiscal '24, compared to 14.1% during the second quarter of last year, and 18.6% for the full fiscal year 2023. This mix shift within our R&D spending is well aligned with our long-term strategy to support increased physician adoption of our med tech platform technologies through the generation of data and clinical evidence.
SG&A expense for the second quarter of FY24 was $34.8 million, representing 44% of sales compared to $36.8 million or 47.8% of sales a year ago. Our adjusted net loss for the second quarter of FY24 was $2 million or adjusted loss per share of $0.05 compared to an adjusted net loss of $3.6 million or adjusted loss per share of $0.09 in the second quarter last year. Adjusted EBITDA in the second quarter of FY24 was $1.8 million compared to adjusted EBITDA of $2.3 million in the second quarter of FY23.
In the second quarter of fiscal '24, we generated $5.3 million in operating cash, had capital expenditures of $0.6 million, and additions to Auryon placement and evaluation units of $1.2 million. At November 30, 2023, we had $60.9 million in cash and cash equivalents compared to $44.6 million in cash and cash equivalents at May 31, 2023. And as a reminder, we have zero debt on the balance sheet.
Turning now to guidance, we now anticipate that FY24 revenue will be in the range of $320 million to $325 million below our prior guidance of $328 million to $333 million. This accounts primarily for the softer thrombectomy sales during the fiscal second quarter, which we now expect will continue throughout the back half of the year as well as certain SKU rationalization and other impacts associated with the manufacturing restructuring we announced this morning.
We now expect full year adjusted loss per share to be in the range of $0.35 to $0.42. We expect FY24 gross margin to be in the range of 49% to 51% compared to pro forma FY23 gross margin of 50.5% as a result of the mix shift occurred due to the lower expected med tech revenue. For FY24, we now expect med tech revenue growth in the range of 10% to 15%, down from 20% to 25% to account for the thrombectomy weakness we saw during the second quarter persisting through the remainder of this year.
We continue to expect med device revenue growth in the range of 1% to 3%. We now expect med tech gross margins in the range of 61% to 63% and med device gross margins in the range of 43% to 45%. As we mentioned earlier, we expect the manufacturing restructuring to have a meaningful impact on our margin structure over the coming years and look forward to providing you with more details as that work gets underway in the coming months.
Today's announcement is a significant step in our strategic transformation that gets us closer to the company we strive to be, a profitable business focused on unique, medical technology platforms that improve patient outcomes in large, underpenetrated, high-growth markets. Finally, I would like to thank our team here at AngioDynamics for their hard work and commitment, and we're looking forward to sharing more about these initiatives with you in the coming months, while executing further on our strategy and delivering a strong second half of fiscal 2014.
With that, I'll turn it back to Jim.

Thanks, Steve, and for those joining, thank you for your time this morning. What you see as a company in transformation, looking to do the balance today of making sure our investments and costs that we spend are aligned to the outcomes that we want to see in the markets we serve, the markets we seek to grow in, taking out significant structural costs. We don't have a lot of product or customer benefit or important steps in that.
We'll continue to do that with an eye to the bottom line, but also maintaining investments to optimize the opportunity that we've set forth in front of us. We have unique opportunities in large and fast-growing markets. We want to make sure we can maximize the opportunity to treat cardiovascular disease, primarily in venous or [material] needs. We also know that our unique NanoKnife can treat solid tumors in areas like prostate cancer. We look forward to following our customers to where they seek to grow with our products.
Thanks for joining us today. Rob, I'll turn it back to you.

Question and Answer Session

Operator

(Operator Instructions)
Yi Chen, H.C. Wainwright.

Thank you for taking my questions. I just want to clarify, the gross margin, will it continue to decrease until you complete the shift to also a third party manufacturer?

You'll see some back and forth, Yi. Thanks for the question. There are going to be costs that are going to be taken out through this process. You're going to see the most impactful benefit come when we are able to finally close the doors and do that full shift to the manufacturing.
[As] we head into giving you guidance to for future years as we move into '25 and '26, we'll give you a little bit more clarity around the cadence from that. So I would expect you're going to see a little bit of movements, but with that most significant movement coming at the end of the two-year period and then certainly being there for the full year FY27.

And Yi, during that two-year period as well. The product mix shift as the med tech products that have a higher gross margin than our corporate gross margin average will become a faster growing piece. So as long as, what Steve said, as we take those costs out of the backend, we also expect to see a mix shift that's positive throughout that three-year cycle and far beyond. Thanks.

Thank you. And regarding the sales from thrombectomy, are there any factors that you expect to drive the sales, increase the sales in the coming year?

There are, Yi, first of all, with AngioVac, again, announcing the breakthrough designation that we received from the FDA a few months back and then getting that IDE aligned to our expectations, the graph to the right heart vegetation opportunity that we think is significant for AngioVac by larger than that AlphaVac. Yi, we mentioned on the call earlier that we look forward to have our CE mark in the first half of calendar year 2024, opens up a significant market for us, and it's timed almost on the same series that will get, we believe, our FDA indication for our PE for the F18 here in the US.
So over the next six months, we'll work hard to educate and train our sales and clinical teams and get ready to go to the markets that we can serve. These are really large markets. What we've learned during the APEX study from AlphaVac that physicians really like the novel design features in the products. The study would not have been completed as fast as it was if people didn't see the novel design elements that led to what we think are really positive patient outcomes. So Yi, really we've got to sit tight for a bit and make sure we're prepared for our full global launch later in calendar 2024.

That's very helpful. Thank you very much.

Operator

Jon Young, Canaccord Genuity.

Hey, Jim, you can you hear me okay?

Thanks, Jon. Good morning.

Good morning. Thanks for taking our question. Just maybe on AngioVac to start, can you go more a little bit more in detail about the headwinds they are talking about? I know in the past you put new sales leadership and training there, and you recently got the breakthrough device designation, the Right Heart Vegetation. What isn't working there, and what you can do to remedy this?

Jon, for AngioVac, it's been a challenge. We mentioned before that we service a smaller market opportunity with AngioVac than we do with AlphaVac. So opening up that Right Heart Vegetation opportunity that we're working with the FDA on is important for us. But again, AngioVac is only going to serve a limited market.
What we've done since we talked to you last summer, brand new sales leader who is terrific, built a new sales team around people that were here already that knew the products, wanted to working in this environment when we opened up these new markets, and AlphaVac PE being the largest. We've also fully realized now a new training module, and we fully staffed our sales force for the first time.
So we're really ready. We're in a phase now. We're training, developing their capabilities, getting them educated in the markets they will serve, both for AngioVac, as you mentioned, which is complex, as you know, and limited, and a larger, less limited markets that has open to us in the future on the AlphaVac PE becomes granted. So we're doing our work on the back-end, training and educating our teams, our clinical and sales teams, to open up these markets.

Great. Thanks, Jim. And then just on shifting to AlphaVac 2, you mentioned that the 2.0 that's in our launch this calendar year. Can you talk about the improvements, and are you going to seek any ASP increases with that? And can you maybe just talk about today the pricing versus the market, and your pricing on par or above or below target? Thank you.

Yeah, good question, Jon. So AlphaVac is really a unique and novel device. And again, I'll let the study speak for itself. Hopefully, you'll see some data being published this calendar year with study results when they become available. But there's some design elements that are unique. For instance, physicians are so used to placing wires when they're treating this part of the anatomy and guiding catheters through the anatomy, which is torturous with usually guidewires and so forth.
We designed the AlphaVac with one of the unique design elements that you don't need to drop a wire or place a wire. Most physicians look at it, like, wait a minute, you can't do that, and they still can do that if they choose. But over time, we found they get confident and comfortable with the design elements of the device. They don't need to do that. It allows them this durability options we've built in to go back and forth between the different parts of the atrium and to really treat the body in a different way. It's faster and safer, we believe.
So some really unique design elements that are already built in the product, that we've heard great feedback on. And we've collected other feedback from some design enhancements they like to see. And that's what we'll offer later this calendar year when we come out with our second gen product, which is timed really well with what we think will be our PE indication expansion.
Today, Jon, we talked about the pricing in the market is in the $8,000 mark. In that range we think is uniquely priced right to be competitive with the other products out there. And the value that our customers received, we think has been really high. They've really shown a willingness to adapt that price point. It's a good price point for us in this market.
I can't speak to other companies. We know where they price their product. Some do it differently, but we think we're in a good spot there. The product will have a high gross margin at that range, and we look to grow in that range of pricing for years to come.

Great. Thank you so much.

Operator

Jayson Bedford, Raymond James.

Good morning, guys, and happy new year here. Just a few questions. On the AlphaVac improvements, just from a regulatory standpoint, do they require an additional 510(K) or can you launch them without any new regulatory approvals?

Hi, Jayson. So the regulatory team is working with the R&D team. So I think that one of the enhancements actually acquires a new 510(K) and one does not. So there's these design changes that were planned in and with the R&D and regulatory teams. So that's why we're looking at that second half of this calendar year -- it's a cycle that our regulatory teams, quality teams, and R&D teams have targeted. We feel confident we'll hit those cycles.

Okay. And then just on thrombectomy, you mentioned some procedural softness late in the quarter. I'm just wondering, what do you attribute the softness to?

We obviously measure this very closely with our customers, and we saw that softness occur in that November timeframe and we talked to our customers. We had two things happening. There is actually a wind down. We're getting very close to the end of the APEX study and our study sites knew that. So some were finishing up. Some were winding down. So we're kind of careful how we measure this.
But we also had a lot of conversations with our customers with quote-unquote same-store sales, people who use a certain amount of the product. The usage went down, we spoke to them and a couple almost shrugged their shoulders a bit and said, hey, we haven't seen the patients come through lately at the rate they normally do, less controlled they had or we had over that marketplace.
It was not huge but enough for us as a still small business for us, AlphaVac getting growing. So it's impactful for us. We watch it closely. So there's a couple of factors there. We don't want to put our arms around any one in particular.
Again, the opportunity that we have with training and education of our team, getting them ready for the PE launch later this calendar year, we think is most impactful. Whether there's a bit of softness back and forth what really matter then because the upside opportunity we believe is significant for us.

And have you seen a bit of a rebound in December?

Yeah, a little bit, step back a little bit, not a whole lot. Again, as I said, we're measuring it differently. And also, Jayson, we have the other factor where -- there was the first couple of days in December were the final patients were enrolled. So we completed the study in the first couple days of December, which really enabled us to shut down the study and then pull back, obviously, on the education of the study.
We can't sell a market-to-product outside of the study terms until we get the PE market. So there's a couple of moving parts having at the same time. Just want to make you aware that. So we're watching all those elements together.

And just -- what's the logistical process of moving to a fully outsourced model? How is this going to work?

Yeah, so we have a -- sites here in upstate New York that we started almost when our company was founded 35 years ago in upstate New York. We got two manufacturing sites, distribution sites as well. So what we'll do is a two-year wind down, Jayson. The announcement we made yesterday starts that two-year process. So we talked to our people at the site yesterday. This has been planned for, you can imagine, 9 to 12 months, the planning phase.
And you've also seen, a couple of years ago, we started moving some of the operations to Costa Rica because we needed capacity. During the pandemic period, we had less availability of new employees and operators. So we started some of those moves for our med device products during that period. So we now have established protocols with some good supplier partners (technical difficulty) validation metrics are set up. That part of our supply chain and works well.
So it gave us the confidence we can move more things and do more if we couldn't get the capacity and cost levels where we need to be. And overtime, we couldn't. So we had this plan B in our pocket. And as I said earlier, as you see, the bulk of our revenue today in our med tech segment comes from suppliers that are partners in our supply chain today.
So back to logistics. We've got a wind down around each of those product segments that are still manufactured in our sites here and a plan around each of those, to move those to a supplier partner and make sure that the quality operations are ready, the validations and all the regulatory processes are in place. That's what we have really, a two-year window, Jayson, to complete that cycle.

Okay. Just maybe a last one for me for now. Cash flow. I think you had a goal out there, $65 million, $70 million cash exiting the year. Is that still on the table?

Jayson, there will be a little bit of moving parts when you think about the manufacturing transfer that we just talked about. For example, there's probably going to be some cash that's going to move from one spot on the asset on the balance sheet to another spot, right? We're going to build up a little inventory as we prepare for some of these movements.
That being said, as Jim said, this is a plan that we've been working on for a very long time. There may be some shifts in the balance sheet, but it's not going to fundamentally change our expectations of where we're going to end up.

So -- sorry, still $65 million to $70 million or towards the low end?

I would expect it would be a little bit below that. But like I said, expect that there's going to be some shifting as you had cash that might move into inventory buildup as we prepare. So that will be a little bit less cash, but maybe not terribly different when you think about current assets.

Okay. Thank you.

Operator

Steven Lichtman, Oppenheimer.

Thank you. Good morning, guys. I guess just, first, a couple of cleanup questions on the manufacturing shift. What percent of med device is outsourced currently, and what anticipated cash costs of the transition should we assume?

So, Steve, with respect to your first question, roughly 20% of the current device portfolio was already made by third party manufacturing partners. Jim mentioned that we had started this process a number of quarters ago as we were building up capacity with our Costa Rica partnership. So we're going to continue doing that. I think it's important to understand that this process that we're talking about is really a continuation of something that was started over the last 24 months or so.
Jim talked about it taking the full 24 months. That's to the point where we can get there and it's fully outsourced. And the benefit that that gives us is, as opposed to today, where we have to have a management structure that supports both this hybrid, company owned manufacturing structure as well as managing the outsource structure, we're going to move to one, which is really going to be one of the fundamental drivers of that $15 million annual savings that we talked about once we can finish this two year process, and then you're going to see that fully roll into FY27.
In terms of the investment, there's going to be investment of something. As Jim said, we've been planning for the last nine months. It's something that is well within our plans and the payback for these types of procedures are always very good. It just was just what you'd expect to see.

Okay. Just sticking to Auryon, can you provide some more color on the pre-op headwinds you mentioned and what you're seeing on that front as we've gone into this fiscal quarter?

Yeah, thanks, Steve. We did touch upon on our Q1 call. We touched upon it. We've seen it out there. I think one or two other companies in the meantime have talked about it in more detail than we have. We got a balancing thing here. We've got still really strong demand being created by Auryon and how it works and the data it's generating and the excitement in the marketplace. So we've got this cool tailwind of interest in Auryon.
I was at our Global Symposium a month-and-a-half ago overseas watching new doctors be trained and talk about the capability of Auryon. So you got that cool tailwind of interest. But yeah, there is a headwind that's been created. We've seen it in the field. So the pre-authorizations, which have always kind of been a part of the cycle, have tightened up and more players are in on it.
So it has slowed down procedures. We are working with industry groups and our customers to go through that process. We haven't come out and said [it] stopped procedures or slowed them down significantly, but it has made an impact. There's no doubt. You still saw growth in a strong quarter. We think the quarter would have been stronger and more procedures would have been done without this headwind. We're doing all we can to work with our customers to minimize it. But it is there.

Thanks, Jim. And then I guess just lastly, I don't think you mentioned anything today about indication expansion for Auryon, including this small vessel, the key, and potentially coronary? Any update on those?

Yeah, a couple of things. So with Auryon, again, we have in our cycle now, a regulatory cycle of MDR, for a European CE approval in the first half of calendar year. We're always a bit cautious, as you know, our industry -- the MDR process has been a challenge for all of us the past couple of years. But the regulatory team has a good aspect of control. We think we'll have Auryon approved overseas in the first half of the calendar year.
Second here, we want to expand Auryon two ways in the US, some of which is part of those six product launches I told you about earlier in the call, one of which happens almost immediately here. Our new radial catheter gets launched as we speak. That's really exciting. There's some other things happening with Auryon beyond just those two things as clinicians see what it can do.
There's been a study called FARO that was completed in Europe last summer and is being published showing how it can be used safely and effectively for coronary applications. We look forward to understanding that study working with the thought leaders that produced it and looking with the FDA working with them on a study protocol and design.
We'll talk more about soon about how we can also embark on the study here in the US to open up a coronary expansion. So we think that's the next natural move for Auryon. As we know, it will be safe and effective in that market.

And nothing new on small [vessel] -- talking back to (technical difficulty)?

No new news there follows the schedule we put forward. We're doing the work on our process now. Our R&D teams and regulatory teams are working on that pathway we laid out before. So there's really no new news out, Steve, on that front.

Okay. Got it. Thanks, Jim. Thank you.

Thank you, Steven.

Operator

Thank you. At this time, I'll turn the call over to Mr. Clemmer for any closing remarks. Mr. Clemmer?

Thank you for joining us today. We appreciate the hard work and commitment of the AngioDynamics employees. It's very difficult to work in an environment as fast paced as the med tech environment, especially when your company is transforming itself, through our portfolio first and second into how we do what we do. So today's announcement of our manufacturing construction is significant for our company.
We think we can better utilize some of those stranded costs that are there that don't drive product to customer or company's benefit. We're going to really allocate those costs over the next few years. Some will go to the bottom line, and some will be allocated to investments, opening up expansion opportunities that exist in these new technologies we're launching.
We're a company in transformation. But we're a strong company with a direction that's clear to make our company more valuable for our customers, for our employees, and our investors. Thank you for joining us today.

Operator

Thank you. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.